Archive: 31/10/2013

AstraZeneca profits and revenues fall

British drugmaker AstraZeneca reported Thursday that third-quarter net profit fell 17.5 percent to 1.25 billion pounds ($200 billion) as the patents on older drugs expired.

Results of DUTCH PEERS (TWENTE II) trial reported

Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish ...

Results of the ARCTIC-INTERRUPTION trial presented

According to a new study, patients that do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT). Results from the ...

Results of the OPTIMIZE trial presented

A new study demonstrates that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration ...

page 3 from 9